Globus Medical, Inc. Class A Common Stock (GMED)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 46% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 11.0% — below-average profitability
- Revenue growing at 17% annually
Globus Medical, Inc. Class A Common Stock (GMED) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $10.9 billion . Key value metrics: P/E ratio 20.8, P/B ratio 2.30, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Globus Medical, Inc. Class A Common Stock — Fundamental Analysis Summary
Globus Medical, Inc. Class A Common Stock (GMED) is currently trading 46% above its Graham Number of $54.90, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 20.8x.
On financial health, GMED shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 11.0% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.16.
StockPik's composite Value Score for GMED is 81/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GMED reports a high gross margin of 67.6% (sector average: 39.4%) and a solid operating margin of 16.0%.
GMED shows revenue growing at 17% year-over-year, with earnings growing at 422%.